Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025
The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 8:30 a.m. Eastern Time on that day to discuss the Company's financial results and outlook.
The Q2 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at https://investor.informatechtarget.com.
Conference Call Dial-In Information:
United States (Toll Free): 1-833-470-1428
United States: 1-404-975-4839
United Kingdom (Toll Free): +44 808 189 6484
United Kingdom: +44 20 8068 2558
Global Dial-in Numbers
Access code: 967110
Please access the call at least 10 minutes prior to the time the conference is set to begin.
Please ask to be joined into the Informa TechTarget call.
Conference Call Webcast Information:
This webcast can be accessed via Informa TechTarget's website at https://investor.informatechtarget.com/
Conference Call Replay Information:
A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through September 11, 2025 at 11:59 p.m. ET. To hear the replay:
United States (Toll Free): 1-866-813-9403
United States: 1-929-458-6194
Access Code: 703085
A web version will also be available for replay during the same period on Informa TechTarget's website at https://investor.informatechtarget.com/
About Informa TechTarget
TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI.
With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market.
Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients:
Trusted information that shapes the industry and informs investment
Intelligence and advice that guides and influences strategy
Advertising that grows reputation and establishes thought leadership
Custom content that engages and prompts action
Intent and demand generation that more precisely targets and converts
Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit informatechtarget.com and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Axon Enterprise (AXON) Vs Palantir Technologies (PLTR): Which is the Better Investment?
Strong Q2 results have led to a further uproar in Axon Enterprise AXON and Palantir Technologies PLTR shares this week, remaining two of the hottest momentum stocks. Axon's stock has now spiked over +40% year to date, with Palantir shares surging more than +130%. More astonishing, AXON is up over +640% in the last three years with PLTR skyrocketing more than 1,700%. Considering their millionaire-maker-like gains, investors are surely wondering which of these hot stocks is the better investment at the moment. Axon Thrives on Increased Public Safety Spending Thanks to increased global defense and public safety spending, Axon easily surpassed its Q2 expectations while posting stellar top and bottom line growth. The innovative manufacturer of weapons for the U.S. and international governments posted Q2 sales of $668.54 million, which soared nearly 33% year over year and comfortably topped estimates of $642.98 billion by 4%. Furthermore, this marked the 14 th consecutive quarter of revenue growth above 25%, with CEO Rick Smith stating Axon is seeing broad demand across the company's portfolio, including for its AI services, drones, cameras, and virtual reality solutions. More impressive, Axon's Q2 earnings came in at $2.12 per share, crushing expectations of $1.54 by 37% and soaring 76% from $1.20 in the prior period. Axon has now exceeded the Zacks EPS Consensus for a remarkable 33 consecutive quarters, with a very impressive average earnings surprise of 25.87% in its last four quarterly reports. Palantir's First Billion-Dollar Quarter Also thriving from increased defense spending, including the securement of a $10 billion contract with the U.S. Army, Palantir achieved its first-ever billion-dollar quarter, topping estimates of $938.33 million. This was a 48% spike from Q2 sales of $678.13 million a year ago, as the software provider saw strong demand for its artificial intelligence platform (AIP) outside of the intelligence communities. Pinpointing increased commercial demand for AIP, Palantir CEO Alex Karp stated that companies are using Palantir's tools not just to optimize operations, but to reshape entire business models. Palantir is also taking advantage of its expansive sales growth, with Q2 EPS of $0.16 rising from $0.09 a share in the comparative quarter and edging expectations of $0.14. Notably, Palantir has now reached of exceeded the Zacks EPS Consensus for 11 consecutive quarters with an average earnings surprise of 13.17% over the last four quarters. Axon & Palantir Raise Their Full-Year Guidance Adding fuel to investor sentiment is that Axon and Palantir have raised their full-year revenue guidance. Optimistically, Axon now forecasts fiscal 2025 revenue at $2.65-$2.73 billion, up from $2.6-$2.7 billion. It's also noteworthy that Axon expects full-year adjusted EBITDA of $665-$685 million, raised from $650-$675 million. Pivoting to Palantir, the company raised its FY25 revenue forecast to $4.142 billion-$4.15 billion, up from previous guidance of $3.89 billion-$3.9 billion. The bump is specifically attributed to full-year commercial revenue guidance increasing to over $1 billion, reflecting at least 85% growth. Additionally, Palantir raised its adjusted income from operations guidance to between $1.912 billion-1.92 billion and increased its adjusted free cash flow guidance to $1.8 billion-$2 billion. Monitoring Axon & Palantir's Valuation While Axon is well ahead in terms of moving further past the probability line than Palantir, the price-to-sales ratio may still be a better indicator of judging the value these hot stocks offer to investors at their current levels, rather than price-to-earnings. That said, Axon is also growing into its lofty valuation more swiftly regarding the P/S ratio after a rebranding to reflect its broader mission in public safety technology. To that point, Axon trades at 25X forward sales, which is far more reasonable than Palantir's 104X. Conclusion & Final Thoughts Although Palantir's ability to benefit from the AI boom makes it the better momentum stock at the moment, Axon appears to be the overall better investment when considering its more justifiable valuation. Axon's profitability also makes it a more sound investment, and earnings estimate revisions (EPS) have remained higher, correlating with AXON sporting a Zacks Rank #1 (Strong Buy). On the other hand, Palantir stock lands a Zacks Rank #3 (Hold), and investors may certainly be looking for better entry points given PLTR doesn't offer much fundamental value after such a monstrous year-to-date rally. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
Key Points The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. These 10 stocks could mint the next wave of millionaires › Just after market close, Adaptive Biotechnologies (NASDAQ: ADPT) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%. That was far higher than the 0.7% lift of the S&P 500 index that day. MRD for the win The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting minimal residual disease (MRD), a cancer disorder in which a relatively small number of cancer cells remain in the body -- and thus present a threat -- after medical treatment. Adaptive revealed that its MRD business was responsible for 85% of the quarter's revenue. Its take grew 42% year over year. At the bottom of the profit and loss statement, Adaptive recorded a net loss of $25.6 million ($0.17 per share). This was much narrower than the more than $46 million deficit of 2024's Q2. With those numbers, the company scored an easy twin beat on the consensus analyst estimates. Those folks were modeling only $49 million and change for revenue, and a significantly deeper net loss of $0.24 per share. A key revenue stream should flow harder On the back of that encouraging growth in the MRD sphere, Adaptive raised its guidance for both the revenue from that business and cash burn. It now expects that MRD will bring in $190 million to $200 million across the entirety of 2025, up from its previous projection of $180 million to $190 million. It did not proffer any guidance for its other major revenue stream, immune medicine. As for cash burn, over the year, it should be $45 million to $55 million. The preceding forecast called for $50 million to $60 million. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
an hour ago
- Globe and Mail
Certara (CERT) Q2 Revenue Jumps 12%
Key Points GAAP revenue beat expectations at $104.6 million in Q2 2025, Revenue reached $104.6 million, representing a 12% increase compared to Q2 2024, while Non-GAAP EPS of $0.07 missed the $0.10 estimate. Software segment revenue jumped 22%, far outpacing the 5% reported growth in services. GAAP net loss narrowed substantially, but the company remains unprofitable on a GAAP basis. These 10 stocks could mint the next wave of millionaires › Certara (NASDAQ:CERT), a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue beat, with reported GAAP revenue of $104.6 million, exceeding analyst expectations, but non-GAAP earnings per share (EPS) missed consensus by $0.03. The company delivered double-digit top-line growth, driven primarily by its software segment, but the bottom line continues to face pressure. GAAP net losses narrowed sharply year over year. Overall, the quarter was marked by continued software momentum but mixed progress on translating growth into profit. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change Revenue (GAAP) $104.6 million $104.05 million $93.3 million 12% EPS (Non-GAAP) $0.07 $0.10 $0.07 0% Adjusted EBITDA $31.9 million $26.3 million 21% Net Income (GAAP) $(2.0) million $(12.6) million 84.1% Software Revenue $46.7 million $38.2 million 22.3% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Inside Certara's Business and Focus Areas Certara operates at the intersection of life sciences and software technology. Its main products are biosimulation platforms, which help pharmaceutical companies simulate how drugs interact within the body using computer models. This approach helps reduce the time, cost, and risk of drug development. The company is well known for its expertise in Model-Informed Drug Development (MIDD), using advanced software, artificial intelligence, and regulatory science tools to help drugs reach the market faster and with higher rates of approval. Recent focus areas include expanding AI and machine learning across its software suite, integrating new technologies through acquisitions, and supporting clients as regulatory agencies encourage the use of biosimulation in preclinical and clinical drug research. Quarterly Trends: Software Strength and Margin Expansion The quarter's headline was the continued rapid growth in software, which delivered a 22% year-over-year increase in revenue. This segment includes products like Simcyp and both software tools used in simulating drug action and regulatory reporting, as well as new offerings powered by artificial intelligence. Revenue from software reached $46.7 million, driven by both organic sales and the integration of Chemaxon, an acquired software company that added $5.3 million in revenue and $5.4 million in bookings. On the services side, growth was slower, with GAAP revenue up only 5%. Biosimulation services remain the primary growth lever in the services business, though increased services bookings of 15% suggest some future revenue potential. Regulatory science and compliance services also maintained demand, especially as the US Food and Drug Administration (FDA) moves toward new drug evaluation standards that rely more on computer modeling and less on animal testing. The recently launched Non-Animal Navigator solution, which combines simulation software and regulatory expertise for monoclonal antibody drug development, received strong early interest, with significant inbound inquiries and over 400 webinar attendees in the weeks following the announcement. However, its financial impact is not expected to be immediate. Certara's bookings—a forward-looking metric measuring new customer contracts—grew 13%. The software bookings component rose 11% year-over-year. The increase in software bookings was primarily due to strength in Certara's core biosimulation software and the contribution from Chemaxon. Growth in bookings for the services segment was even stronger at 15%, suggesting recovery momentum in this area even as the segment's revenue growth lags. Cost of revenue (GAAP) increased 2.3% compared to Q2 2024, much less than total revenue growth. Operating expenses declined by $8.2 million, reflecting sharp drops in items like transaction costs. Adjusted EBITDA—a measure of core profitability—jumped 21% year over year, with adjusted EBITDA margin rising to about 30% for the year. Still, adjusted net income and non-GAAP EPS were flat versus a year earlier, signaling ongoing pressure from high non-cash costs like stock-based compensation. Strategy: Innovation, Acquisitions, and Regulatory Momentum Certara continues to invest heavily in research and development, particularly around artificial intelligence and new biosimulation models. The launch of the platform and the company's AI-powered software tools stand out as key differentiators in the market, with Research and development expense (GAAP) was $8.972 million, compared to $9.067 million for Q2 2024. These investments aim to make its software easier to use and more effective for drug developers as the regulatory landscape shifts toward model-based approaches. The company is integrating recent acquisitions, notably Chemaxon, to expand its software range and customer reach. Since 2013, Certara has acquired 21 businesses, giving it access to cutting-edge technology and expertise while achieving greater global scale. Certara's software and services have been used by more than 2,400 biopharmaceutical companies and academic institutions across 70 countries, including 38 of the top 40 pharmaceutical companies by research and development spending. On the regulatory front, Certara's work spans 23 drug regulatory agencies globally, and its tools have contributed to the majority of new drug approvals by the FDA over the last decade. The FDA's recent move to phase out animal testing for some types of drugs has created new opportunities for Certara's biosimulation products and services. The Non-Animal Navigator solution—combining software models and scientific consulting—was launched to help drug developers adapt to these new guidelines and reduce their reliance on animal models in the preclinical stage. The treasury share buyback program continues, with 3.2 million treasury shares held as of June 30, 2025, up from 950,000 at the end of December 2024. Looking Ahead: Management Guidance and Key Watchpoints For the full fiscal 2025 year, Certara reiterated its full-year 2025 guidance on August 6, targeting revenue of $415–$425 million for FY2025, adjusted EBITDA margins of 30–32% for the full year, and adjusted diluted EPS of $0.42–$0.46 for FY2025. These figures suggest expected top-line growth in the high single digits and stable profit margins, based on Certara's full-year 2025 guidance for revenue of $415 million to $425 million and adjusted EBITDA margin of 30% to 32%. Management noted steady demand for biosimulation and increasing customer interest in model-informed solutions, but Certara reiterated its guidance for the full fiscal year. Investors should watch for signs of improvement in the services segment, and ongoing regulatory changes—particularly the FDA's support for biosimulation and alternatives to animal testing—could create new business opportunities, but financial materiality will likely take time to emerge. Persistent GAAP net losses, high stock-based compensation, and the challenge of translating robust revenue gains into net profit remain critical issues for Certara as it continues to invest in its transformation strategy, as evidenced by a GAAP net loss of $2.0 million and equity-based compensation expense of $8.2 million. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025
